| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 1 Oct 2026 | 28 Sep 2026 |
| Employees Stock Option Plan & Inter alia, to consider and approve the following: 1. The proposal for establishment of Senior Executive Employee Stock Option Plan 2026 2. The proposal for the establishment of Employee Stock Option Plan 2026 Please find enclosed herewith the outcome of the Board Meeting held today i.e. Thursday, October 01, 2026 through Video Conferencing or Other Audio Visual Means. (As Per BSE Announcement Dated on:01.10.2026) | ||
| Board Meeting | 28 Sep 2026 | 28 Sep 2026 |
| Please find enclosed herewith Outcome of Board Meeting held on September 28, 2026, pursuant to the consummation of the transaction contemplated in the share purchase agreement dated May 23, 2026. | ||
| Board Meeting | 12 Aug 2026 | 5 Aug 2026 |
| Quarterly Results We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026, through Video Conferencing (VC)/Other Audio-Visual Means (OAVM), with the deemed venue being the Registered Office of the Company. Pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matter amongst others: 1.The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. A copy of the unaudited standalone and consolidated financial results, along with the Limited Review Report of the Auditors, are enclosed below. 2.The draft of the Postal Ballot Notice seeking the approval of members of the Company for the appointment of Mr. Santosh Parab (DIN: 01622988) as a Director of the Company in the capacity of Non-Executive Non-Independent Director of the Company. (As Per BSE Announcement Dated on:12.08.2026) | ||
| Board Meeting | 3 Jul 2026 | 3 Jul 2026 |
| Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, at its meeting held today, i.e., Friday, July 03, 2026, through Video Conferencing (VC)/Other Audio-Visual Means (OAVM), with the deemed venue being the Registered Office of the Company inter-alia has considered and approved the: 1. Appointment of Mr. Santosh Parab (DIN:01622988) as an Additional Director in the capacity of Non-Executive Non-Independent Director w.e.f. July 03, 2026. 2. Appointment of Mr. Rahul Adakmol as Chief Executive Officer of the Company with effect from July 15, 2026. 3. Mr. Narsimha Shibroor Kamath has stepped aside from the position of Chief Executive Officer with effect from close of business hours on July 14, 2026, while continuing to serve as the Managing Director of the Company. | ||
| Board Meeting | 23 May 2026 | 23 May 2026 |
| Please find herewith the outcome of Board Meeting held on May 23, 2026 | ||
| Board Meeting | 12 May 2026 | 5 May 2026 |
| Audited Results & Final Dividend We would like to inform you that the Board Meeting of the Company was held today i.e. on Tuesday, May 12, 2026, at the registered office of the Company. In pursuance of Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved items as mentioned in the attachment. (As Per BSE Announcement Dated on : 12.05.2026) | ||
| Board Meeting | 10 Feb 2026 | 3 Feb 2026 |
| Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 inter alia to consider and approve 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2025. 2. The Interim Dividend if any for the financial year 2025-2026. The Board Meeting of Bliss GVS Pharma Limited (the Company) was held today i.e. Tuesday, February 10, 2026, at the registered office of the Company has considered and approved the following matter(s) amongst others- 1. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025. A copy of unaudited Standalone and Consolidated Financial Results of the Company, along with the Limited Review Report of the Auditors of the Company for the quarter and nine months ended December 31, 2025, are enclosed herewith as Annexure-1; and 2. Declared the Interim dividend of 50% i.e. 0.50 paisa per equity share on face value of Re.1/- each for the financial year 2025-2026. The Interim Dividend shall be paid within 30 days from the date of its declaration. (As Per BSE Announcement Dated on:10.02.2026) | ||
| Board Meeting | 23 Dec 2025 | 23 Dec 2025 |
| We would like to inform you that, the Board Meeting of the Company was held today i.e. on Tuesday, December 23, 2025, at the registered office of the Company through Video Conferencing. In pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters as enclosed herewith. | ||
| Board Meeting | 6 Nov 2025 | 29 Oct 2025 |
| Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2025. Please find attached herewith the Outcome of Board Meeting held on Thursday, November 06, 2025. Please find attached the Resignation of Mr. Gagan Harsh Sharma, Managing Director of the Company with effect from November 06, 2025. (As Per BSE Announcement Dated on 06.11.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
